



## PULMONOLOGY

www.journalpulmonology.org



## REVIEW

## Vaccination in post-tuberculosis lung disease management: A review of the evidence

M.J. Nasiri<sup>a</sup>, D.R. Silva<sup>b</sup>, F. Rommasi<sup>a</sup>, M.M. Zahmatkesh<sup>a</sup>, Z. Tajabadi<sup>a</sup>, F. Khelghati<sup>a</sup>, T. Sarmastzadeh<sup>a</sup>, R. Centis<sup>c</sup>, L. D'Ambrosio<sup>d</sup>, S. Bombarda<sup>e</sup>, M.P. Dalcolmo<sup>f</sup>, T. Galvão<sup>g</sup>, F.C. de Queiroz Mello<sup>h</sup>, M.F. Rabahi<sup>i</sup>, E. Pontali<sup>j</sup>, I. Solovic<sup>k,l</sup>, M. Tadolini<sup>m,n</sup>, L. Marconi<sup>m</sup>, S. Tiberi<sup>o</sup>, M. van den Boom<sup>p</sup>, G. Sotgiu<sup>q</sup>, G.B. Migliori<sup>c,\*</sup>

<sup>a</sup> Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

<sup>b</sup> Faculdade de Medicina, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil

<sup>c</sup> Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy

<sup>d</sup> Public Health Consulting Group, Lugano, Switzerland

<sup>e</sup> Secretaria de Estado da Saúde de São Paulo, Programa de Controle da Tuberculose, São Paulo, Brazil

<sup>f</sup> Referência Center Hélio Fraga, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil

<sup>g</sup> Serviço de Pneumologia, Hospital Especializado Octávio Mangabeira, Secretaria de Saúde do Estado da Bahia, Salvador, Brazil

<sup>h</sup> Thorax Diseases Institute, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil

<sup>i</sup> Faculdade de Medicina, Universidade Federal de Goiás (UFG), Goiânia, Brazil

<sup>j</sup> Department of Infectious Diseases, Galliera Hospital, Genoa, Italy

<sup>k</sup> Department of Public Health, Faculty of Health, Catholic University, Ruzomberok, Slovakia

<sup>l</sup> National Institute of Tuberculosis, Pulmonary Diseases and Thoracic Surgery, Vysne Hagy, Slovakia

<sup>m</sup> Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

<sup>n</sup> Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy

<sup>o</sup> Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, E1 2AT United Kingdom

<sup>p</sup> World Health Organisation, Regional Office for the Eastern Mediterranean Region, Cairo, Egypt

<sup>q</sup> Clinical Epidemiology and Medical Statistics Unit, Department of Medicine, Surgery and Pharmacy, University of Sassari, Italy

Received 20 April 2023; accepted 10 July 2023

Available online xxx

### KEYWORDS

*Mycobacterium tuberculosis*;  
Post-tuberculosis lung disease;  
Respiratory infections;  
Vaccination

### Abstract

**Introduction and objectives:** Post-tuberculosis lung disease (PTLD), as other chronic respiratory disorders, may have infectious complications; some of them can be prevented with vaccinations. So far, no document has discussed the potential role of vaccination in PTLD. Therefore, the objective of this review was to describe vaccination recommendations to prevent infections potentially capable of complicating PTLD.

\* Corresponding author at: Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Via Roncaccio 16, 21049 Tradate, Italy.

E-mail address: giovannibattista.migliori@icsmaugeri.it (G.B. Migliori).

<https://doi.org/10.1016/j.pulmoe.2023.07.002>

2531-0437/© 2023 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Please cite this article in press as: M.J. Nasiri, D.R. Silva, F. Rommasi et al., Vaccination in post-tuberculosis lung disease management: A review of the evidence, Pulmonology (2023), <https://doi.org/10.1016/j.pulmoe.2023.07.002>

**Materials and methods:** A non-systematic review of the literature was conducted. The following keywords were used: tuberculosis, vaccination, vaccines and PTLD. PubMed/MEDLINE and Embase were used as the search engine, focusing on English-language literature only.

**Results:** We identified 9 vaccines potentially useful in PTLD. Influenza, pneumococcal and anti-COVID-19 vaccinations should be recommended. Patients with PTLD can also benefit from vaccination against shingles. Vaccination against pertussis is mainly relevant during childhood. Diphtheria, tetanus and measles vaccination are recommended for general population and should be considered in patients with PTLD not previously vaccinated. Tdap (Tetanus, diphtheria, and pertussis) booster should be repeated in every adult every ten years. Vaccination against BCG retains its importance during early childhood in countries where TB is endemic.

**Conclusions:** Vaccination deserves to be considered among the strategies to prevent and/or mitigate PTLD complications. Further evidence is necessary to better understand which vaccines have the greatest impact and cost-benefit.

© 2023 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Introduction

Tuberculosis (TB) is a public health priority annually affecting 10 million people, responsible for 1.6 million deaths in 2021,<sup>1</sup> currently, the second leading infectious killer after COVID-19.<sup>2,3</sup> Due to the complex interaction between *Mycobacterium tuberculosis*, host genetic factors, and immune response, 13 to 96% of patients with pulmonary TB suffer from post-tuberculosis lung disease (PTLD) after completing treatment.<sup>4,5</sup> The World Health Organization (WHO) has estimated that from 2000 to 2020, nearly 66 million people survived tuberculosis; more than half still suffering from PLTD.<sup>2</sup> Thus, PTLD is an important cause of chronic lung disease which was ignored for the past fifty years.<sup>6</sup>

PTLD, defined in 2019 as “evidence of chronic respiratory abnormality, with or without symptoms, attributable at least in part to previous pulmonary tuberculosis”,<sup>3,7,8</sup> is a chronic respiratory disorder causing abnormalities such as bronchiectasis,<sup>9</sup> and obstructive/restrictive lung disease affecting, with potential ongoing inflammation and associated tissue damage, the different components of the lungs (large and small airways, lung parenchyma, pulmonary vasculature, and pleura).<sup>3,10</sup>

Pathological features of PTLD range from modest signs and symptoms to severe dysfunction sustained by cavitation, fibrosis (both mild and severe), bronchiectasis, small-airway disease, airway stenosis, fibrosing mediastinitis, fibrothorax, and bronchopleural fistulas.<sup>3,11-15</sup>

As a result, PTLD patients often report residual cough, weakness, dyspnea, difficulties in climbing stairs (and performing other exercises) or managing every-day or work activities, which affect their quality of life (QoL) and increase the risk of death,<sup>8,16-18</sup> while increasing the risk of recurrent TB.<sup>7</sup>

Heterogeneity in lung damage might be related to differentiation in genes that code or regulate host immune responses, host-pathogen interactions, and various immunological events.<sup>11</sup> Potential risk factors for increasing the severity of the chronic condition PTLD are smoking (including passive), exposure to dust and biomass fuel as well as concomitant respiratory tract infections.<sup>6,13,14,19-21</sup> HIV coinfection (depending on immunological status), *Mycobacterium tuberculosis* virulence, delays in diagnosis and start of

appropriate anti-TB treatment as well as genetic variability of the patient could also be involved.<sup>5,11,18,22</sup>

Although no evidence-based international guidelines for the management of PTLD are available<sup>7</sup>, a recent consensus document summarized the Clinical Standards for PTLD assessment, management and rehabilitation (Table 1).<sup>4,9,23</sup>

Treatment and rehabilitation suitable for other chronic pulmonary diseases (chronic obstructive pulmonary disease or COPD, asthma, bronchiectasis among others) have been recommended for PTLD as well.<sup>4,9,23,24</sup>

Among the interventions discussed to prevent or mitigate the effects of PTLD smoking cessation, pulmonary rehabilitation, as well as vaccination, have been mentioned.<sup>25</sup>

In fact, PTLD as other chronic respiratory disorders may be complicated by viral, bacterial and fungal diseases as well as *non-tuberculous mycobacteria* (NTM); some of them can be prevented with existing vaccinations.<sup>26</sup>

So far, no document has discussed the potential role of vaccination in preventing or mitigating the effects of PTLD.

In this review we describe the potential role of the existing vaccinations to prevent the commonest infections potentially able to further complicate PTLD.

## Methods

A non-systematic review of the literature was conducted by the members of the writing committee (including clinicians, public health and methodology experts), so as to include useful core references that may help the reader better understand the topics covered. The following keywords were used, without any time limitation: ‘tuberculosis’, ‘vaccination’, ‘vaccines’ and ‘PTLD’. The search query used the words ‘vaccination’ or ‘vaccines’ in combination with either ‘tuberculosis’ or ‘PTLD’. PubMed/MEDLINE and Embase were used as the search engine, focusing on the English-language literature only.

The records were found through database searching and merged; duplicates were removed using EndNote X7 (Thomson Reuters, Toronto, ON, Canada). Two reviewers (MMZ, ZT) independently screened the records by title/abstract and full text to include those related to the study objectives. If disagreement arose a third reviewer was asked to provide own input (MJN).

**Table 1** Clinical manifestations, associated-disease patterns, imaging findings, and treatment strategies of post-tuberculosis lung disease.

Clinical manifestations <sup>27,-29</sup>	Dyspnea /Cough /Sputum /Hemoptysis /Wheezing / Chest pain / Peripheral edema /Clubbing /Fever /Recurrent infections/Weakness		
Disease patterns <sup>7</sup>	Obstructive	COPD /Bronchiectasis	
	Restrictive	Pulmonary fibrosis /Pulmonary cavitation /Pulmonary destruction	
Imaging findings <sup>28-31</sup>	Other	<i>Aspergillus</i> infection /Pleural disease /Pulmonary hypertension /Mixed pulmonary diseases (both obstructive and restrictive)	
	Chest radiography	Fibrosis /Traction /Pneumothorax /Cavitation /Destruction /Hyperinflation /Increased cardiothoracic ratio /Pleural reaction /Pleural thickening /Infiltration /Nodules /Mediastinal lesions /Consolidation	
		Computerized tomography	Cystic /Cylindrical /Varicose /Tractional bronchiectasies/Consolidation /GGO /Reticulation / Cavitation /Fibrosis /Pleural thickening /Nodules /Emphysema/Bullae /Mosaicism /Fibrotic bands /Mass /Parenchymal calcification /Opacity /Architectural distortion
Treatments <sup>32</sup>	Surgery	Causes	Hemorrhage /Spontaneous pneumothorax /Recurrent hemoptysis /Localized cavitary disease with persistent sputum positivity /Empyema /Continuously positive smear and/or culture /Pulmonary Aspergillosis /Fibrocavitary TB /Cavitary TB /Tuberculoma with destruction /Caseous pneumonia /Intrathoracic lymph nodes /Relapsed TB/Cancer
		Types	Lobectomy /Segmentectomy /Pneumonectomy /Partial resection /Arterial embolization
	Rehabilitation	Outcomes	Improved quality of life /Improved lung function /Improved exercise capacity /Improved walking capability

Legend: COPD: chronic obstructive pulmonary disease; GGO: ground glass opacity; TB, tuberculosis.

All authors, gave their input in writing specific sections of the manuscript and revising the full paper. Four versions of the manuscript were revised by the writing committee, and the final version was approved by consensus (100% agreement).

The level of evidence of the articles used in this study regarding recommendations for vaccination in PTLT patients or others is available in [Table 2](#).<sup>33</sup>

### Vaccines potentially useful to prevent or mitigate PTLT complications

A summary of these vaccines is presented in [Table 3](#) (in order of priority) with the recommended indications and schedule.

### Influenza

Influenza is a disease caused by a group of viruses known for various epidemics they caused throughout history. Epidemics usually occur during winter (seasonal outbreaks). However, sporadic pandemics may happen in all seasons based on geography and climate. Influenza virus can strike various organs, and its symptoms emerge as a fever associated with a spectrum of systemic and respiratory symptoms.<sup>54</sup> The first human influenza virus was isolated about 90 years ago, in 1933, which led to the production of the first live attenuated influenza vaccine. Later the first inactivated vaccine, a monovalent vaccine against type-A influenza, was produced. Following that, bivalent, trivalent, and even quadrivalent vaccines against different strains of type-A and type-B influenza virus were developed. The influenza virus mutates quickly (antigenic shift and drift). This high-speed mutation

**Table 2** Level of evidence on vaccination in PTLTD patients and other conditions, in other chronic respiratory conditions and in the general population.

Title	Vaccine	Year	Author(s)	Level of evidence
Post tuberculosis treatment infectious complications	Influenza	2020	Hsu et al. <sup>34</sup>	5
Influenza vaccination in immunocompromised populations: strategies to improve immunogenicity	Influenza	2021	Caldera et al. <sup>35</sup>	5
Pneumococcal vaccination and chronic respiratory diseases	Pneumococcal vaccine	2017	Froes et al. <sup>36</sup>	5
Tuberculosis and COVID-19 co-infection in Serbia: pandemic challenge in a low-burden country	COVID-19	2022	Adzic-Vukicevic et al. <sup>37</sup>	2b
COVID-19 vaccination in pregnancy, paediatrics, immunocompromised patients, and persons with history of allergy or prior SARS-CoV-2 infection: overview of current recommendations and pre- and post-marketing evidence for vaccine efficacy and safety	COVID-19	2021	Luxi et al. <sup>38</sup>	5
Tuberculosis and COVID-19 co-infection: description of the global cohort	COVID-19	2022	TB/COVID-19 Global Study Group <sup>39</sup>	2b
Measles vaccines: WHO position paper, April 2017 - recommendations	Measles	2019	WHO <sup>40</sup>	5
Effect of measles prevalence and vaccination coverage on other disease burden: evidence of measles immune amnesia in 46 African countries	Measles	2021	Sato and Haraguchi <sup>41</sup>	4
Measles vaccines may provide partial protection against COVID-19	Measles	2020	Saad and Elsalamony <sup>42</sup>	5
Risk factors for herpes zoster: should people with asthma or COPD be vaccinated?	Herpes zoster	2023	Safonova et al. <sup>43</sup>	5
Risk factors for herpes zoster infection: a meta-analysis	Herpes zoster	2020	Marra et al. <sup>44</sup>	2a
Risk of Herpes Zoster in patients with pulmonary tuberculosis—a population-based cohort study	Herpes zoster	2023	Wang et al. <sup>45</sup>	2b
The unmet need for pertussis prevention in patients with chronic obstructive pulmonary disease in the Italian context	Pertussis	2020	Blasi F et al. <sup>46</sup>	5
Prevention of pertussis, tetanus, and diphtheria with	Pertussis, Tetanus, Diphtheria	2018	Liang et al. <sup>47</sup>	5

Table 2 (Continued)

Title	Vaccine	Year	Author(s)	Level of evidence
vaccines in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP)				
The association between tuberculosis and diphtheria	Diphtheria	2018	Coleman <sup>48</sup>	5
Diphtheria and tetanus vaccination history is associated with lower odds of COVID-19 hospitalization	Tetanus	2021	Monereo-Sánchez et al. <sup>49</sup>	3b
Tetanus vaccination is associated with differential DNA-methylation: reduces the risk of asthma in adolescence	Tetanus	2016	Janjanam et al. <sup>50</sup>	2b
Does BCG vaccination protect against nontuberculous mycobacterial infection? A systematic review and meta-analysis	BCG	2018	Zimmermann et al. <sup>51</sup>	1a
Effect of BCG vaccination against <i>Mycobacterium tuberculosis</i> infection in children: systematic review and meta-analysis	BCG	2014	Roy et al. <sup>52</sup>	2a
Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials	BCG	2014	Mangtani et al. <sup>53</sup>	1a

Legend: PTLD: post-tuberculosis lung disease; TB: tuberculosis; MDR: multidrug-resistant; WHO: World Health Organization; BCG: Bacillus Calmette–Guérin.

Level of evidence<sup>33</sup> 1a: systematic review of (homogeneous) randomized controlled trials; 1b: individual randomized controlled trials (with narrow confidence intervals); 2a: systematic review of (homogeneous) cohort studies of "exposed" and "unexposed" subjects; 2b: individual cohort study / low-quality randomized control studies; 3a: systematic review of (homogeneous) case-control studies; 3b: individual case-control studies; 4: case series, low-quality cohort or case-control studies; 5: expert opinions based on non-systematic reviews of results or mechanistic studies.

helps the virus to reshape as novel strains, leading to lower vaccine efficacy. Since 1973 WHO has published annual instructions on vaccine composition according to the circulating strains in each specific period.<sup>55</sup>

Both inactivated and live-attenuated vaccines activate the innate and adaptive immune systems. This leads to the secretion of inflammatory cytokines, interleukins, interferons, and the production of immunoglobulins (IgA, IgG1, and IgM).<sup>56</sup> Immunocompromised patients, such as patients with HIV infection, are more vulnerable to influenza complications, putting them at higher risk of severe morbidity and mortality. WHO has recommended annual influenza vaccination for these patients; however, effective vaccination is challenging due to their incompetent immune systems.<sup>35</sup> Patients affected by chronic respiratory conditions are more prone to suffer from influenza complications or influenza can exacerbate their pulmonary disease.<sup>57-59</sup> United States (US) Centers for Disease Control and Prevention (CDC)

describes common side effects of flu vaccination as headache, fever, nausea, myalgia and redness of the injection site. However, severe allergic reactions can occasionally occur.<sup>60</sup> According to most international guidelines, vaccinating patients with chronic respiratory diseases against influenza is recommended, particularly those over 65 years of age. Since influenza and chronic lung conditions including PTLD can lead to higher morbidity and mortality, seasonal influenza vaccination should be recommended in PTLD patients<sup>34</sup> (Table 3, with priority criteria for vaccination).

### Pneumococcal disease

Pneumococcal disease can be categorized into either invasive or non-invasive disease. Invasive disease happens when *Streptococcus pneumoniae* is isolated from a normally sterile site. This includes pneumococcal meningitis, bacteremic pneumococcal pneumonia, and pneumococcal bacteremia

**Table 3** Suggested prioritization and schedule for vaccination in subjects with PTLT.

Vaccine	Schedule	Comments
Vaccines for which evidence is available to be recommended for chronic respiratory conditions and PTLT		
Influenza	- 1 dose annually; adults and children > 6 months	
Pneumococcal	- 1 dose PCV15 OR 1 dose PCV20. If PCV15 is used, this should be followed by a dose of PPSV23 given at least 1 year after the PCV15 dose; adults > 18 years	
COVID-19	- 2- or 3-dose primary series and booster; adults and children > 6 months	
Vaccines recommended for the general population (or specific age-groups) of which PTLT patients are likely to benefit		
Measles	- 1 dose if no evidence of immunity (born before 1957, documentation of receipt of MMR (measles, mumps, and rubella) vaccine, laboratory evidence of immunity or disease)	if no evidence of immunity
Herpes zoster	- 2-dose series recombinant zoster vaccine (RZV, Shingrix), 2–6 months apart, regardless of previous herpes zoster or history of zoster vaccine live (ZVL, Zostavax) vaccination; adults > 50 years	if > 50 years
Pertussis	- Children (part of the regular vaccination schedule) - Tdap (Tetanus, diphtheria, and pertussis) vaccine to every adult who has not received it as an adolescent: 3 doses with a minimum interval of 4 weeks between the first and the second dose, and an interval of at least 6 months between the second and a third dose. Two subsequent booster doses using Td or Tdap combination vaccines are needed with an interval of at least 1 year between doses. - Tdap booster dose every 10 years	if not previously vaccinated, booster dose every 10 years
Diphtheria	- Children (part of the regular vaccination schedule) - Tdap (Tetanus, diphtheria, and pertussis) vaccine to every adult who has not received it as an adolescent: 3 doses with a minimum interval of 4 weeks between the first and the second dose, and an interval of at least 6 months between the second and a third dose. Two subsequent booster doses using Td or Tdap combination vaccines are needed with an interval of at least 1 year between doses. - Tdap booster dose every 10 years	if not previously vaccinated, booster dose every 10 years
Tetanus	- Children (part of the regular vaccination schedule) - Tdap (Tetanus, diphtheria, and pertussis) vaccine to every adult who has not received it as an adolescent: 3 doses with a minimum interval of 4 weeks between the first and the second dose, and an interval of at least 6 months between the second and a third dose. Two subsequent booster doses using Td or Tdap combination vaccines are	if not previously vaccinated, several countries recommend booster dose every 10 years

**Table 3** (Continued)

Vaccine	Schedule	Comments
	needed with an interval of at least 1 year between doses. - Tdap booster dose every 10 years	
BCG	- During early childhood (a single dose to all healthy neonates at birth) in countries where TB is endemic	during childhood in TB endemic countries. Potential non-specific protection role

Legend: PTLD: post-tuberculosis lung disease; PCV15: 15-valent pneumococcal conjugate vaccine; PCV20: 20-valent pneumococcal conjugate vaccine; PPSV23: 23-valent pneumococcal polysaccharide vaccine.

without a primary focus. On the other hand, non-invasive diseases can be divided into otitis media, sinusitis, and community-acquired pneumonia.<sup>61</sup> *Streptococcus pneumoniae* was first discovered in 1881. The first trials to produce a whole-cell vaccine were largely unsuccessful which brought vaccine development to a halt for a relatively long time.

Moreover, the success of penicillin led to the loss of enthusiasm for pneumococcal vaccines. Eventually, in 1977, the first 14-valent purified polysaccharide vaccine was approved for public use. Later in 1983, the vaccine-based immunization expanded to 23 capsular polysaccharides. A 7-valent conjugate vaccine was licensed in 2000 to be used in children under two years of age as their immune system response to polysaccharide antigens is relatively low.<sup>62,63</sup>

Vaccine antigens induce B cells to produce antibodies (IgM, IgG2, IgG1). This humoral immunity against pneumococcal capsule is the core mechanism of immunity. However, cell-mediated immunity plays its role by augmenting B-cell responses.<sup>63</sup> According to CDC, common side effects of vaccination are redness and tenderness of the injection site, fever, loss of appetite, irritability, fatigue, headache, myalgia and chills. These conditions usually resolve within two days.<sup>64</sup>

At present, there are two kinds of pneumococcal vaccines available:

- Pneumococcal conjugate vaccines (PCV13, PCV15, and PCV20)
- Pneumococcal polysaccharide vaccine (PPSV23)

Evidence suggests that pneumococcal vaccination can prevent community-acquired pneumonia in patients with chronic respiratory diseases.<sup>36</sup> Thus, it is expected that patients with PTLD, like patients affected by other chronic respiratory diseases, can benefit from pneumococcal vaccination.

CDC recommends pneumococcal vaccination (either PCV13 or PCV15) for all children younger than 2 years of age and for children 2 through to 4 years old who are unvaccinated or received an incomplete pneumococcal vaccine series.<sup>65</sup>

For adults above 65 years of age, conjugate vaccine (PCV 15) followed by polysaccharide vaccine (PPSV23) one year later is recommended, to stimulate a more vigorous immunity. In cases of certain medical conditions, such as chronic lung disease, CDC recommends conjugate vaccination (PCV

15) followed by polysaccharide vaccine (PPSV23) one year later both in children and adults. Where the new conjugate vaccine (PCV20) is used, the polysaccharide vaccine PPSV23 is not indicated.<sup>65</sup>

Vaccination for pneumococcal disease represents one of the most important preventive strategies in subjects with COPD and should be prioritized for individuals with PTLD (Table 3).

## COVID-19

Coronavirus disease 2019 (COVID-19) is a contagious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Patients with SARS-CoV-2 infection may present various clinical symptoms. These mainly include cough, fever, fatigue, hyposmia, headache, nausea, and diarrhea. As of February 12, 2023, more than 755 million cases were confirmed, and more than 6.8 million deaths of COVID-19 reported to WHO globally.<sup>66,67</sup> According to the records, it appears that the COVID-19 outbreak started on December 12, 2019, in Wuhan, China, and attempts to discover a vaccine started soon after that.<sup>68</sup>

As of today, numerous vaccines are produced against COVID-19. These vaccines are categorized as an inactivated, viral vector, live attenuated, RNA and DNA, and virus-like particle (VLP) vaccines.<sup>69</sup> According to CDC, possible side effects of vaccination include fatigue, headache, myalgia, chills, fever, nausea and redness of the injection site. Each type of COVID-19 vaccine may have specific side effects.<sup>70</sup>

Evidence shows that COPD patients have worse outcomes from COVID-19 due to multiple biological mechanisms including micro-thrombosis, the effects of intrapulmonary shunting and secondary bacterial infection.<sup>71</sup> For these reasons COPD patients should be prioritized for COVID-19 vaccination.<sup>72</sup> Adzic-Vukicevic et al. conducted a retrospective analysis on TB and COVID-19 co-infection. They concluded that vaccination against SARS-CoV-2 may be beneficial in patients with current or past TB disease, including those suffering from PTLD.<sup>37,39</sup> Given COVID-19 impacts on both patients with PTLD and TB, its use has already been recommended as a priority in these settings.<sup>73-77</sup>

Since immunocompromised patients (patients with malignancy, organ transplant recipients, patients with HIV, etc.) are at higher risk of severe SARS-CoV-2 infection, they are prioritized for COVID-19 vaccination<sup>38</sup> (Table 3).

## Pertussis

Pertussis (also known as whooping cough) is a highly contagious vaccine-preventable disease. Symptoms of pertussis start with rhinorrhea, lacrimation, congestion of respiratory mucosa, conjunctival hyperemia, sore throat, and coughs, which deteriorate as the disease progresses.<sup>78</sup> Historically, pertussis disease was recognized centuries ago. However, its causative agent, *Bordetella pertussis*, was discovered in 1906, leading to the invention of a whole-cell pertussis vaccine in 1914. This significantly decreased the morbidity and mortality from pertussis.<sup>79</sup>

Two types of pertussis vaccine are categorized as a whole-cell vaccine (wP) and acellular vaccine (aP), respectively. As its name suggests, the whole-cell vaccine contains the entire inactivated cell of *Bordetella pertussis*, while the acellular vaccine contains only some specific antigens. Whole-cell vaccines are associated with more side effects in comparison to acellular vaccines; however, they are more efficacious.<sup>78</sup> According to CDC, common side effects of the combined diphtheria, tetanus and acellular pertussis (DTaP) vaccine are swelling of the injection site, fever, irritability, fatigue, vomiting and loss of appetite which are mild to moderate in severity and can last 1–3 days.<sup>80</sup> Whole-cell pertussis vaccine induces immunity mainly through Th1 and Th17-mediated responses by activating CD4+ T cells. Acellular vaccines, in contrast, primarily induce Th2-mediated responses.<sup>81</sup> Vaccination during infancy and early childhood induces and maintains immunity against pertussis for several years. However, immunity may wane in older age leading to disease resurgence. Thus, many researchers have mentioned the need to modify immunization schedules to reduce circulation within families and thus guarantee protection for young children and adults at risk of complications.<sup>82</sup>

Emerging data shows that individuals with COPD are at high risk of contracting pertussis. Furthermore, those who develop pertussis could experience exacerbation of their pre-existent COPD and further susceptibility to other infections, leading to increased rate of hospitalization and direct medical costs compared to controls (patients without a diagnosis of COPD).<sup>46,83</sup> Patients suffering from PTLD share several clinical and pathological characteristics with chronic lung disease such as COPD, asthma, bronchiectasis.<sup>4,9,23,24</sup> Thus, pertussis vaccination is expected to have a positive impact among them, too.<sup>46,83</sup>

To prevent pertussis, US CDC recommends diphtheria, tetanus, and pertussis (DTaP) vaccines in children below 7 years of age, and Tdap (tetanus, diphtheria, and pertussis vaccine) for children 7 years and older, adolescents, and adults. Pregnant people should get a dose of Tdap during every pregnancy, preferably during the early part of the third trimester, to help protect the newborn from pertussis, as infants are most at risk of severe, life-threatening complications from pertussis. Adults who have never received Tdap should get a dose of Tdap, and this also applies to patients with chronic respiratory disease. Also, adults should receive a booster dose of either Tdap every 10 years<sup>84</sup> (Table 3).

## Herpes zoster

Varicella zoster virus (VZV) is a type of human herpesvirus that can cause two different diseases. These are primary

infection (also known as chickenpox) and reactivation of latent infection (herpes zoster or shingles). Shingles emerges as a vesicular rash that extends along dermatomes. The first varicella vaccine was developed in Japan in 1974 as a live-attenuated vaccine and was used to reduce morbidity and mortality among immunocompromised children.<sup>85</sup> ZVL, a live attenuated vaccine, was the first FDA-approved vaccine to be used against herpes zoster in 2006. Later in 2017, FDA approved RZV, an adjuvanted recombinant zoster vaccine, for adults over 50 years of age. In 2021 FDA further approved RZV for adults aged  $\geq 18$  years with increased risk for herpes zoster due to immunosuppression or immunodeficiency.<sup>43</sup> The latter vaccine, SHINGRIX, stimulates cytokine production and promotes CD4+ T-cell responses and antigen-specific antibody production.<sup>86</sup> Side effects of Shingrix include tenderness and redness of the injection site, fatigue, myalgia, headache, fever, chills and nausea. Symptoms usually resolve within 2–3 days.<sup>87</sup> A recent meta-analysis revealed that COPD increases the risk of herpes zoster by 41%.<sup>44</sup> Moreover, a COPD patient is more likely to develop post-herpetic neuralgia following herpes zoster.<sup>43</sup> CDC suggests routine use of shingles vaccine in patients with lung diseases.<sup>88</sup> A recent cohort study concluded that pulmonary TB, as a stressor, significantly increases the risk of herpes zoster occurrence.<sup>45</sup> Thus, it seems that patients with PTLD, similarly to patients with COPD, can benefit from vaccination against shingles (Table 3).

## Diphtheria

Diphtheria is an acute respiratory infection caused by toxin-producing bacteria from the *Corynebacterium* genus. The discovery of diphtheria antitoxin, penicillin, toxoid vaccine, and mass vaccination significantly reduced morbidity and mortality from diphtheria. Thus, it has recently escaped researchers' attention.<sup>89</sup> There were diphtheria epidemics centuries before Pierre Bretonneau named it in 1826. In 1914 a safe mixture of toxins and antitoxins was used for immunization. Later diphtheria toxoid was developed, and mass immunization of schoolchildren began. Since 1974 WHO has included diphtheria toxoids along with tetanus and pertussis vaccines (DTP) in childhood vaccination programmes.<sup>90</sup>

Diphtheria toxoid-based vaccine is a purified formulation of inactivated diphtheria toxin. This toxoid induces immune responses to produce antibodies against toxins.<sup>91</sup> Although diphtheria is controlled in the majority of countries, many outbreaks were recorded last century. Therefore, the risk of potential resurgence and seizures should be considered.<sup>90</sup> It is recommended that individuals living in areas of low endemicity should receive a booster dose of diphtheria toxin every ten years after the first series of vaccination, as diphtheria immunity wanes throughout ones life.<sup>47</sup> Based on historical reports, in a tuberculosis-diphtheria co-infection, the severity of either disease intensifies. Also, a severe diphtheria infection may "re-awake" an earlier tuberculosis infection.<sup>48</sup> Thus, diphtheria vaccination should be considered in not previously vaccinated PTLD patients, as in general population (Table 3).

## Tetanus

Tetanus disease, previously known as lockjaw, is caused by a gram-positive, obligatory anaerobic bacteria called



*Clostridium tetani*, which is often found in soil and feces in the environment and can turn into a progressive, fatal condition.<sup>92,93</sup> Tetanus is typically caused by these bacteria entering the body through wounds, cuts, abrasions, or punctures in cutaneous or mucosal barriers. Also, in rare cases, surgical procedures, intravenous drug injections, and animal/insect bites may lead to tetanus.<sup>92</sup> Once entered, *Clostridium tetani* migrates into the nervous system, where it begins to produce tetanospasmin, which usually causes muscle rigidity, autonomic system dysfunction, and muscular spasms, and tetanolysin, the exact function of which is not fully understood.<sup>94</sup> Although global immunization with the tetanus toxoid vaccine since 1940 has led to a dramatic reduction in tetanus infection and mortality rates, tetanus still leads to thousands of deaths worldwide, especially in low and middle-income countries where the immunization rate is low. In 2015, more than 56,700 tetanus-related deaths occurred, with Asia and Sub-Saharan Africa accounting for 45% and 44% of mortalities, respectively.<sup>95</sup> Since not having immunization from tetanus remains a significant risk factor for tetanus development and mortality, many communities still recommend and perform tetanus vaccination for the whole population.<sup>95</sup>

The first administration of tetanus toxoid as a vaccine with the purpose of tetanus prevention goes back to 1924. To obtain the toxoid vaccine, *Clostridium tetani* is cultured in a liquid media, and then, the toxin is obtained, purified, and becomes inactivate using formaldehyde and is further formulated with mineral salts, such as aluminum and calcium.<sup>96</sup> Till 1938, several advances were made in developing a safer and more effective tetanus toxoid vaccine. Since 1940, the tetanus vaccine has become widely used worldwide.<sup>97</sup> Leading to a remarkable reduction in tetanus cases since its emergence, the tetanus toxoid is considered a safe and effective way for tetanus prevention and is a vital part of routine vaccination programmes in almost all countries, usually injected along with diphtheria and pertussis vaccines. Based on WHO recommendations,<sup>98</sup> administration of the first dose of tetanus toxoid should be initiated in infancy at six weeks of age, and the second dose must be injected at least four weeks apart. At six months, the third dose should be given to complete the primary series. In addition to these three primary doses, three booster doses should also be administered, which help to make life-long immunity protection against infection with *Clostridium tetani*. The first booster dose is recommended to be injected at 1–2 years of age, and the second and third booster doses should be administered at least four years apart.<sup>98</sup>

The beneficial effects of the tetanus vaccine come mainly through the induction of immune response. Once injected, the tetanus toxin activates T helper cells and B cells, which further work together to produce and secrete cytokines that provide immune protection against the natural toxins of *Clostridium tetani*.<sup>99</sup>

Since the majority of the immune response against *Clostridium tetani* is based on antibodies that wane through time, the administration of periodic booster doses of tetanus toxoid is recommended to provide lifelong protection against the disease.<sup>100</sup>

However, uncertainty exists about if and when to provide booster doses in adults. Some countries and organizations, such as the United Kingdom and the WHO do not recommend

additional dosage after adolescence (but they do not recommend against it), while in other countries the recommendation is to provide a booster dose of Td (tetanus, diphtheria) or Tdap every 10 years or more.<sup>84,101–105</sup>

Although scarce, a few studies revealed the non-specific effects of the tetanus vaccine in various infectious diseases in addition to tetanus. Recently, a growing body of literature showed a possible association between the history of tetanus vaccination and the risk and/or severity of COVID-19 infection. Regarding this issue, Monereo-Sánchez et al. demonstrated that individuals with a history of receiving tetanus vaccine during the last ten years were at a lower risk of developing severe COVID-19.<sup>49</sup> Moreover, some evidence indicating the protective effect of tetanus vaccination against developing some respiratory disorders, such as asthma, in adolescence has been found.<sup>50</sup> Although the association between tetanus vaccination and TB or PTLD has not been well studied yet, in accordance with previous studies regarding the heterologous effects of tetanus toxoid vaccine on respiratory infections and diseases, the vaccine might be able to exert some beneficial effects on TB or its associated pulmonary disorders (Table 3). However, more evidence on this is required.

## Measles

Measles, characterized and annotated by Thomas Sydenham in the 17th century, is a highly contagious infectious disease caused by the ribonucleic acid (RNA) respiratory measles virus.<sup>106,107</sup> Typically, measles presents with progressive fever, maculopapular rash initiating from the face and spreading to the whole body surface, coryza symptoms, and Koplik spots, which are pathognomonic of the disease.<sup>108</sup> In addition to the abovementioned typical symptoms, measles can be accompanied and complicated by severe respiratory, gastrointestinal, neurological, and ocular manifestations.<sup>106,109,110</sup> Being highly contagious, the measles virus led to several outbreaks in many parts of the world before the development and broad implementation of the vaccine.<sup>111</sup>

The measles vaccine was first developed in 1954 when Thomas Chalmers Peebles and John Franklin Enders separated the measles virus from the nasopharyngeal sample of a child and cultured the virus on a culture consisting of primary human kidney cells.<sup>112,113</sup> A live attenuated vaccine was developed by further passaging the isolated virus in renal, amnion, and embryo fibroblast cells.<sup>112</sup> The protection against measles infection is mostly caused by the vaccine-induced activation of both humoral and cellular immune responses.<sup>107</sup> Following measles vaccination, T cells are activated, which then contribute to the production of antibodies by B cells, especially those against the H protein of the measles virus. These B cell-produced antibodies usually provide the vaccine recipient with long-lasting protection against measles infection.<sup>114,115</sup>

This live attenuated vaccine was very successful in reducing the incidence of measles infection and associated mortality. Nowadays, based on the WHO recommendations, all susceptible individuals should receive two doses of the measles vaccine.<sup>40</sup> Mainly, the measles vaccine is administered in combination with the mumps and rubella vaccines (MMR). It has been stated that reaching a vaccine coverage of 95%

or higher can result in measles elimination in any region.<sup>40</sup> Thanks to the contribution of the measles vaccine, a 79% reduction in measles cases and a 94% reduction in measles-related mortality occurred from 2000 to 2020.<sup>116</sup> However, despite a high vaccination rate in most countries, measles can still cause outbreaks in some regions.<sup>108</sup> According to CDC, side effects of vaccination with the MMR vaccine may include tenderness and redness of the injection site, fever, mild rash and temporary pain and stiffness of the joints.<sup>117</sup>

In addition, to provide outstanding protection against measles infection, some studies have previously shown that the measles vaccine might be helpful in reducing the burden of some other diseases. For instance, Sato et al. showed that measles vaccination was associated with not only a reduction in measles cases and deaths but also a lower prevalence and mortality of diarrhea, low respiratory infections, malaria, meningitis, and TB.<sup>41</sup> More recently, a few studies suggested that a history of vaccination with the measles vaccine might lead to a lower rate of COVID-19 infection and mortality, in part due to the activation of the immune system and the non-specific effects of the vaccine on all-cause mortality. However, the potential association is not well studied yet and needs further evaluation.<sup>42</sup> Although further evidence is necessary, a rationale exists to consider this vaccination in unvaccinated individuals suffering from chronic respiratory diseases (and for PTLD), as in the general population at large (Table 3).

## BCG

The first and early research activities of Albert Calmette and Camille Guérin for developing a vaccine against *Mycobacterium tuberculosis* were conducted in early 1900 at the Pasteur, Lille, France.<sup>118</sup> Historically, to generate an effective vaccine, the virulent *Mycobacterium bovis* pathogen was passaged by Calmette and Guérin on a medium consisting of glycerin, potato, and ox bile.<sup>119</sup> After almost 230 passages since 1908, finally, an attenuated form of *Mycobacterium bovis* was introduced in 1919 which was unable to cause tuberculosis infection in animals and was named *Mycobacterium bovis* bacille Calmette Guèrin (BCG). In 1921, the BCG vaccine was first tested in the human population.<sup>120</sup> Over these 102 years, BCG has been widely used worldwide as the sole effective vaccine against tuberculosis and was associated with promising results regarding the reduction of tuberculosis infection and mortality.<sup>52,120</sup> Nowadays, BCG is considered a primary part of routine vaccination programmes in many countries where TB is endemic. Some countries with a lower prevalence of TB also administer the BCG vaccine to those who are at a high risk of developing and transmitting TB, people like healthcare workers.<sup>121</sup>

Although the exact mechanisms through which the BCG vaccine exerts its beneficial effects against *Mycobacterium tuberculosis* are not fully figured out, it is widely believed that the vaccine affects the host immune system as it builds up a robust and appropriate immune response against the pathogen.<sup>120</sup> It has been shown that BCG could induce both innate and adaptive immune systems as well alter the immune regulatory responses and factors. Once injected, BCG can induce monocytes, macrophages, neutrophils, and dendritic cells to produce cytokines, such as IFN- $\gamma$ , and further activate adaptive immune system components,

including CD4+ and CD8+ T cells to secrete IL-2, TNF- $\alpha$ , and IL-10.<sup>122-126</sup> Although it seems that BCG provides its beneficial effects mostly via activation of the immune system, the exact underlying mechanisms are yet to be understood. Side effects of BCG vaccination include pain and discharge from the injection site, fever, headache and axillary lymphadenopathy. Severe complications such as abscess, osteomyelitis and disseminated BCGitis are rare.<sup>127</sup>

Although the BCG vaccine was primarily developed to combat TB, previous studies have found that BCG vaccination might also have beneficial effects in the prevention of infectious diseases other than TB; proposedly due to its power to activate the immune system response.<sup>128,129</sup> A systematic review and meta-analysis carried out by Zimmermann et al. revealed that the BCG vaccine had a more protective effect against nontuberculous mycobacteria in children who had previously received vaccination than in those without a history of BCG vaccination at birth or childhood.<sup>51</sup> Recently, several studies evaluated the protective effect of the BCG vaccine in COVID-19 infection development;<sup>130-132</sup> however, the results are conflicting. A systematic review and meta-analysis conducted by Li et al. demonstrated that individuals who were previously vaccinated with BCG were at a 0.61-fold lower risk of developing infection with SARS-CoV-2 virus.<sup>133</sup> In contrast, Wen et al. stated that BCG vaccination had no significant effect on COVID-19 development or severity regarding hospitalization, intensive care unit admission, or mortality.<sup>134</sup> Although a growing body of literature has revealed the beneficial off-target effects of BCG vaccine in prevention of various infectious diseases caused by infectious microbial agents other than *Mycobacterium tuberculosis*, such as NTM diseases, these non-specific effects need further evaluation.<sup>51</sup> However, the efficacy of BCG vaccine in prevention of some respiratory disorders has been evaluated. For instance, Li et al. found that children with bronchiolitis who were vaccinated with BCG had a lower risk of developing bronchial asthma than those who were not BCG vaccinated.<sup>135</sup> Despite the efficacy of immunization with BCG in preventing TB has been evaluated in numerous studies,<sup>52,53</sup> data about the impact of BCG vaccination in prevention of PTLD and its adverse outcomes is very scarce and is yet to be understood. In summary, BCG protects against TB and probably has a non-specific role in protecting from other infections, although its role in reducing relapse or reinfection in PTLD remains to be elucidated. Therefore, vaccination against BCG retains its importance during early childhood in countries where TB is endemic, while new and more effective vaccines will be made available for programmatic use (Table 3).

## Research gaps

Several research gaps exist on the role of vaccines in managing subjects with PTLD. Below we report some of them, as a contribution to further discussion:

- Lack of longitudinal data from TB survivors that includes non-TB respiratory infections like pneumococcus, influenza and other lower respiratory tract pathogens.

- What the risk is for a PTLD person of developing Low Respiratory Tract Infections (LRTIs) compared with an age matched control.
- Are LRTIs of similar severity and outcome in PTLD comparable with those in the general population?
- Should all PTLD patients receive vaccination for influenza, pneumococcus, pertussis, Respiratory Syncytial Virus (RSV) or can PTLD patients be placed into subcategories based on risk (i.e., age, HIV status, other comorbidities/immunosuppressive concomitant medications, chest X-ray appearance)?
- Studies are needed to understand the role of *Hemophilus Influenzae* vaccination in subjects with PTLD.
- Further evidence is needed to understand if BCG has a real non-specific effect to protect patients with chronic respiratory conditions.

## Conclusions

Considering the epidemiological relevance of PTLD, the role of vaccination has an important contribution to prevention of complications and/or mitigation of their effects. Immunizing PTLD patients with the available vaccines as primary immune response inducers, or booster doses has been accompanied by considerable benefits. All in all, since PTLD as a chronic respiratory condition impacts on the respiratory system, vaccinating against preventable respiratory infections could efficiently limit secondary infections and further evolution of PTLD damage. Therefore, vaccination deserves to be considered among the strategies to prevent and/or mitigate PTLD, reinforcing the existing recommendations for the general population and emphasizing the need for extended vaccine coverage for PTLD patients regardless of their age. Further evidence from longitudinal studies and modeling is necessary to better understand which vaccines have the greatest impact and cost-benefit.

## Funding source

This work was partially funded by the “Ricerca Corrente” scheme of the Ministry of Health, Italy and by an educational grant of Glaxo Smith Kline to SBPT (Sociedade Brasileira de Pneumologia e Tisiologia).

## Conflicts of interest

None.

## Acknowledgments

The article is part of the scientific activities of the Global Tuberculosis Network (GTN).

The authors thank Luciano Attard (Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy) for his contribution.

## References

1. World Health Organization. Global tuberculosis report 2022. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO. 2022.
2. World Health Organization. Tuberculosis fact sheet. 27 October 2022. <https://www.who.int/news-room/fact-sheets/detail/tuberculosis>, 2022 [accessed 17 April 2023]
3. Singh S, Allwood BW, Chiyaka TL, Kleyhans L, Naidoo CC, Moodley S, et al. Immunologic and imaging signatures in post tuberculosis lung disease. *Tuberculosis (Edinb)*. 2022; 136:102244.
4. Migliori GB, Marx FM, Ambrosino N, Zampogna E, Schaaf HS, van der Zalm MM, et al. Clinical standards for the assessment, management and rehabilitation of post-TB lung disease. *Int J Tuberc Lung Dis*. 2021;25(10):797–813.
5. Migliori GB, Caminero Luna J, Kurhasani X, van den Boom M, Visca D, D’Ambrosio L, et al. History of prevention, diagnosis, treatment and rehabilitation of pulmonary sequelae of tuberculosis. *Presse Med*. 2022;51(3):104112.
6. van Kampen SC, Wanner A, Edwards M, Harries AD, Kirenga BJ, Chakaya J, et al. International research and guidelines on post-tuberculosis chronic lung disorders: a systematic scoping review. *BMJ Glob Health*. 2018;3(4):e000745.
7. Allwood BW, Byrne A, Meghji J, Rachow A, van der Zalm MM, Schoch OD. Post-tuberculosis lung disease: clinical review of an under-recognised global challenge. *Respiration*. 2021;100(8):751–63.
8. Allwood BW, van der Zalm MM, Amaral AFS, Byrne A, Datta S, Egere U, et al. Post-tuberculosis lung health: perspectives from the first international symposium. *Int J Tuberc Lung Dis*. 2020;24(8):820–8.
9. Martinez-Garcia MA, Guan WJ, de-la-Rosa D, Athanasio R, Oscullo G, Shi MX, et al. Post-TB bronchiectasis: from pathogenesis to rehabilitation. *Int J Tuberc Lung Dis*. 2023;27(3):175–81.
10. Muñoz-Torrico M, Rendon A, Centis R, D’Ambrosio L, Fuentes Z, Torres-Duque C, et al. Is there a rationale for pulmonary rehabilitation following successful chemotherapy for tuberculosis? *J Bras Pneumol*. 2016;42(5):374–85.
11. Ravimohan S, Kornfeld H, Weissman D, Bisson GP. Tuberculosis and lung damage: from epidemiology to pathophysiology. *Eur Respir Rev*. 2018;27(147):170077. <https://doi.org/10.1183/16000617.0077-2017>.
12. Willcox P, Ferguson A. Chronic obstructive airways disease following treated pulmonary tuberculosis. *Respir Med*. 1989;83(3):195–8.
13. Amaral AF, Coton S, Kato B, Tan WC, Studnicka M, Janson C, et al. Tuberculosis associates with both airflow obstruction and low lung function: BOLD results. *Eur Respir J*. 2015;46(4):1104–12.
14. Byrne AL, Marais BJ, Mitnick CD, Lecca L, Marks GB. Tuberculosis and chronic respiratory disease: a systematic review. *Int J Infect Dis*. 2015;32:138–46.
15. Ahmed AE, Ibrahim AS, Elshafie SM. Pulmonary hypertension in patients with treated pulmonary tuberculosis: analysis of 14 consecutive cases. *Clin Med Insights Circ Respir Pulm Med*. 2011;5:1–5.
16. Pasipanodya JG, Miller TL, Vecino M, Munguia G, Garmon R, Bae S, et al. Pulmonary impairment after tuberculosis. *Chest*. 2007;131(6):1817–24.
17. Wingfield T, Boccia D, Tovar M, Gavino A, Zevallos K, Montoya R, et al. Defining catastrophic costs and comparing their importance for adverse tuberculosis outcome with multi-drug resistance: a prospective cohort study, Peru. *PLoS Med*. 2014;11(7):e1001675.
18. Meghji J, Lesosky M, Joekes E, Banda P, Rylance J, Gordon S, et al. Patient outcomes associated with post-tuberculosis lung

- damage in Malawi: a prospective cohort study. *Thorax*. 2020;75(3):269–78.
19. GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the global burden of disease study 2015. *Lancet Respir Med*. 2017;5(9):691–706.
  20. Menezes AM, Hallal PC, Perez-Padilla R, Jardim JR, Muiño A, Lopez MV, et al. Tuberculosis and airflow obstruction: evidence from the PLATINO study in Latin America. *Eur Respir J*. 2007;30(6):1180–5.
  21. Ehrlich RI, Adams S, Baatjies R, Jeebhay MF. Chronic airflow obstruction and respiratory symptoms following tuberculosis: a review of South African studies. *Int J Tuberc Lung Dis*. 2011;15(7):886–91.
  22. Wang C, Lin H, Lin S, Huang C, Liu C, Huang K, et al. MMP-1 (-1607G) polymorphism as a risk factor for fibrosis after pulmonary tuberculosis in Taiwan. *Int J Tuberc Lung Dis*. 2010;14(5):627–34.
  23. Pontali E, Silva DR, Marx FM, Caminero JA, Centis R, D'Ambrosio L, et al. Breathing back better! A state of the art on the benefits of functional evaluation and rehabilitation of post-tuberculosis and post-COVID lungs. *Arch Bronconeumol*. 2022;58(11):754–63.
  24. Visca D, Zampogna E, Sotgiu G, Centis R, Saderi L, D'Ambrosio L, et al. Pulmonary rehabilitation is effective in patients with tuberculosis pulmonary sequelae. *Eur Respir J*. 2019;53(3):1802184. <https://doi.org/10.1183/13993003.02184-2018>.
  25. Visca D, Centis R, Munoz-Torrico M, Pontali E. Post-tuberculosis sequelae: the need to look beyond treatment outcome. *Int J Tuberc Lung Dis*. 2020;24(8):761–2.
  26. Joao I, Bujdaková H, Jordao L. Opportunist coinfections by nontuberculous mycobacteria and fungi in immunocompromised patients. *Antibiotics (Basel)*. 2020;9(11):771. <https://doi.org/10.3390/antibiotics9110771>.
  27. de Sousa Elias Nihues S, Mancuzo EV, Sulmonetti N, Sacchi FPC, Viana VDS, Martins Netto E, et al. Chronic symptoms and pulmonary dysfunction in post-tuberculosis Brazilian patients. *Braz J Infect Dis*. 2015;19(5):492–7.
  28. Mkofo P, Naidoo S, Mbanga L, Nomvete F, Muloiwa R, Dlamini S. Chronic lung disease and a history of tuberculosis (post-tuberculosis lung disease): clinical features and in-hospital outcomes in a resource-limited setting with a high HIV burden. *S Afr Med J*. 2019;109(3):169–73.
  29. Bajpai J, Kant S, Verma A, Bajaj DKJC. Clinical, radiological, and lung function characteristics of post-tuberculosis bronchiectasis: an experience from a tertiary care center in India. *Cureus*. 2023;15(2):e34747. <https://doi.org/10.7759/cureus.34747>.
  30. Meghji J, Simpson H, Squire SB, KJPo Mortimer. A systematic review of the prevalence and pattern of imaging defined post-TB lung disease. *PLoS ONE*. 2016;11(8):e0161176. <https://doi.org/10.1371/journal.pone.0161176>.
  31. Wang H, Ji XB, Li CW, Lu HW, Mao B, Liang S, et al. Clinical characteristics and validation of bronchiectasis severity score systems for post-tuberculosis bronchiectasis. *Clin Respir J*. 2018;12(8):2346–53.
  32. Visca D, Tiberi S, Centis R, D'Ambrosio L, Pontali E, Mariani AW, et al. Post-tuberculosis (TB) Treatment: the role of surgery and rehabilitation. *Appl. Sci*. 2020;10(8):2734. <https://doi.org/10.3390/app10082734>.
  33. Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. *Plast Reconstr Surg*. 2011;128(1):305–10. <https://doi.org/10.1097/PRS.0b013e318219c171>.
  34. Hsu D, Irfan M, Jabeen K, Iqbal N, Hasan R, Migliori GB, et al. Post tuberculosis treatment infectious complications. *Int J Infect Dis*. 2020;92S:S41–5. <https://doi.org/10.1016/j.ijid.2020.02.032>.
  35. Caldera F, Mercer M, Samson SI, Pitt JM, Hayney MS. Influenza vaccination in immunocompromised populations: strategies to improve immunogenicity. *Vaccine*. 2021;39(Suppl 1):A15–23.
  36. Froes F, Roche N, Blasi F. Pneumococcal vaccination and chronic respiratory diseases. *Int J Chron Obstruct Pulmon Dis*. 2017;12:3457–68.
  37. Adzic-Vukicevic T, Stosic M, Antonijevic G, Jevtic M, Radovanovic-Spurnic A, Velickovic J. Tuberculosis and COVID-19 co-infection in Serbia: pandemic challenge in a low-burden country. *Front Med (Lausanne)*. 2022;9:971008. <https://doi.org/10.3389/fmed.2022.971008>.
  38. Luxi N, Giovanazzi A, Capuano A, Crisafulli S, Cutroneo PM, Fantini MP, et al. COVID-19 vaccination in pregnancy, paediatrics, immunocompromised patients, and persons with history of allergy or prior SARS-CoV-2 infection: overview of current recommendations and pre- and post-marketing evidence for vaccine efficacy and safety. *Drug Saf*. 2021;44(12):1247–69.
  39. TB/COVID-19 Global Study Group. Tuberculosis and COVID-19 co-infection: description of the global cohort. *Eur Respir J*. 2022;59(3):2102538. <https://doi.org/10.1183/13993003.02538-2021>.
  40. World Health Organization. Measles vaccines: WHO position paper, April 2017 - recommendations. *Vaccine*. 2019;37(2):219–22.
  41. Sato R, Haraguchi MJHV. Immunotherapeutics. Effect of measles prevalence and vaccination coverage on other disease burden: evidence of measles immune amnesia in 46 African countries. *Hum Vaccin Immunother*. 2021;17(12):5361–6.
  42. Saad M, Elsalamony R. Measles vaccines may provide partial protection against COVID-19. *Int J Cancer Biomed Res*. 2020;4(Special Issue):15–9. <https://doi.org/10.21608/jcbr.2020.26765.1024>.
  43. Safonova E, Yawn BP, Welte T, Wang C. Risk factors for herpes zoster: should people with asthma or COPD be vaccinated? *Respir Res*. 2023;24(1):35. <https://doi.org/10.1186/s12931-022-02305-1>.
  44. Marra F, Parhar K, Huang B, Vadlamudi N. Risk factors for herpes zoster infection: a meta-analysis. *Open Forum Infect Dis*. 2020;7(1):ofaa005. <https://doi.org/10.1093/ofid/ofaa005>.
  45. Wang CA, Chen CH, Hsieh WC, Hsu TJ, Hsu CY, Cheng YC, et al. Risk of herpes zoster in patients with pulmonary tuberculosis—a population-based cohort study. *Int J Environ Res Public Health*. 2023;20(3):2656. <https://doi.org/10.3390/ijerph20032656>.
  46. Blasi F, Bonanni P, Braido F, Gabutti G, Marchetti F, Centanni S. The unmet need for pertussis prevention in patients with chronic obstructive pulmonary disease in the Italian context. *Hum Vaccin Immunother*. 2020;16(2):340–8.
  47. Liang JL, Tiwari T, Moro P, Messonnier NE, Reingold A, Sawyer M, et al. Prevention of pertussis, tetanus, and diphtheria with vaccines in the United States: recommendations of the advisory committee on immunization practices (ACIP). *MMWR Recomm Rep*. 2018;67(2):1–44.
  48. Coleman S. The association between tuberculosis and diphtheria. *Epidemiol Infect*. 2018;146(8):940–5.
  49. Monereo-Sanchez J, Luykx JJ, Pinzon-Espinosa J, Richard G, Motazed E, Westlye LT, et al. Diphtheria and tetanus vaccination history is associated with lower odds of COVID-19 hospitalization. *Front Immunol*. 2021;12:749264. <https://doi.org/10.3389/fimmu.2021.749264>.
  50. Janjanam VD, Mukherjee N, Lockett GA, Rezwan FI, Kurukulaarachy R, Mitchell F, et al. Tetanus vaccination is associated with differential DNA-methylation: reduces the risk of asthma in adolescence. *Vaccine*. 2016;34(51):6493–501.
  51. Zimmermann P, Finn A, Curtis NJTJ. Does BCG vaccination protect against nontuberculous mycobacterial infection? A systematic review and meta-analysis. *J Infect Dis*. 2018;218(5):679–87.

52. Roy A, Eisenhut M, Harris R, Rodrigues L, Sridhar S, Habermann S, et al. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. *BMJ*. 2014;349:g4643. <https://doi.org/10.1136/bmj.g4643>.
53. Mangtani P, Abubakar I, Ariti C, Beynon R, Pimpin L, Fine PE, et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. *Clin Infect Dis*. 2014;58(4):470–80.
54. Javanian M, Barary M, Ghebrehewet S, Koppolu V, Vasigala V, Ebrahimpour S. A brief review of influenza virus infection. *J Med Virol*. 2021;93(8):4638–46.
55. Hannoun C. The evolving history of influenza viruses and influenza vaccines. *Expert Rev Vaccines*. 2013;12(9):1085–94.
56. Keshavarz M, Mirzaei H, Salemi M, Momeni F, Mousavi MJ, Sadehghalvad M, et al. Influenza vaccine: where are we and where do we go? *Rev Med Virol*. 2019;29(1):e2014. <https://doi.org/10.1002/rmv.2014>.
57. Huang H-Y, Lo C-Y, Chung F-T, Huang Y-T, Ko P-C, Lin C-W, et al. Risk Factors for influenza-induced exacerbations and mortality in non-cystic fibrosis bronchiectasis. *Viruses*. 2023;15(2):537. <https://doi.org/10.3390/v15020537>.
58. Kim P, Coleman B, Kwong JC, Plevneshi A, Hassan K, Green K, et al. Burden of severe illness associated with laboratory-confirmed influenza in adults aged 50-64 years, 2010-2011 to 2016-2017. *Open Forum Infect Dis*. 2022;10(1):ofac664. <https://doi.org/10.1093/ofid/ofac664>.
59. Liao KM, Chen YJ, Shen CW, Ou SK, Chen CY. The influence of influenza virus infections in patients with chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis*. 2022:2253–61.
60. Centers for Disease Control and Prevention. Flu vaccine safety information. <https://www.cdc.gov/flu/prevent/general.htm>, 2022. [accessed 17 April 2023].
61. Drijkoningen JJ, Rohde GG. Pneumococcal infection in adults: burden of disease. *Clin Microbiol Infect*. 2014;20(Suppl 5):45–51.
62. Briles DE, Paton JC, Mukerji R, Swiatlo E, Crain MJ. Pneumococcal vaccines. *Microbiol Spectr*. 2019;7(6). <https://doi.org/10.1128/microbiolspec.GPP3-0028-2018>.
63. Berical AC, Harris D, Dela Cruz CS, Possick JD. Pneumococcal vaccination strategies: an update and perspective. *Ann Am Thorac Soc*. 2016;13(6):933–44.
64. Centers for Disease Control and Prevention. Pneumococcal vaccination: what everyone should know. <https://www.cdc.gov/vaccines/vpd/pneumo/public/index.html>, 2023. [accessed 17 April 2023].
65. Centers for Disease Control and Prevention. Pneumococcal vaccination: summary of who and when to vaccinate. <https://www.cdc.gov/vaccines/vpd/pneumo/hcp/who-when-to-vaccinate.html>, [accessed 17 April 2023].
66. Forchette L, Sebastian W, Liu T. A comprehensive review of COVID-19 virology, vaccines, variants, and therapeutics. *Curr Med Sci*. 2021;41(6):1037–51.
67. World Health Organization. WHO coronavirus (COVID-19) dashboard. <https://covid19.who.int/>, 2023. [accessed 17 April 2023].
68. Chams N, Chams S, Badran R, Shams A, Araji A, Raad M, et al. COVID-19: a multidisciplinary review. *Front Public Health*. 2020;8:383. <https://doi.org/10.3389/fpubh.2020.00383>.
69. Li M, Wang H, Tian L, Pang Z, Yang Q, Huang T, et al. COVID-19 vaccine development: milestones, lessons and prospects. *Signal Transduct Target Ther*. 2022;7(1):146. <https://doi.org/10.1038/s41392-022-00996-y>.
70. Centers for Disease Control and Prevention. Possible side effects after getting a COVID-19 vaccine. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/expect/after.html>, 2022. [accessed 17 April 2023].
71. Singh D, Mathioudakis AG, Higham A. Chronic obstructive pulmonary disease and COVID-19: interrelationships. *Current opinion in pulmonary medicine*. *Curr Opin Pulm Med*. 2022;28(2):76–83.
72. Gerayeli FV, Milne S, Cheung C, Li X, Yang CWT, Tam A, et al. COPD and the risk of poor outcomes in COVID-19: a systematic review and meta-analysis. *EClinicalMedicine*. 2021;33:100789. <https://doi.org/10.1016/j.eclinm.2021.100789>.
73. Rodrigues I, Aguiar A, Migliori GB, Duarte R. Impact of the COVID-19 pandemic on tuberculosis services. *Pulmonology*. 2022;28(3):210–9. <https://doi.org/10.1016/j.pulmoe.2022.01.015>.
74. Visca D, Ong CWM, Tiberi S, Centis R, D'Ambrosio L, Chen B, Mueller J, Mueller P, Duarte R, Dalcolmo M, Sotgiu G, Migliori GB, Goletti D. Tuberculosis and COVID-19 interaction: a review of biological, clinical and public health effects. *Pulmonology*. 2021;27(2):151–65. <https://doi.org/10.1016/j.pulmoe.2020.12.012>.
75. Migliori GB, Thong PM, Alffenaar JW, Denholm J, Tadolini M, Alyaquobi F, et al. Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study. *Eur Respir J*. 2021;58(5):2101786. <https://doi.org/10.1183/13993003.01786-2021>.
76. García-García JM, Blanc FX, Buonsenso D, Centis R, Codecasa LR, D'Ambrosio L, et al. COVID-19 hampered diagnosis of TB infection in France, Italy, Spain and the United Kingdom. *Arch Bronconeumol*. 2022;58(11):783–5.
77. Nalunjogi J, Mucching-Toscano S, Sibomana JP, Centis R, D'Ambrosio L, Alffenaar JW, et al. Impact of COVID-19 on diagnosis of TB, MDR-TB and on mortality in 11 countries in Europe, Northern America and Australia. A global tuberculosis network study. *Int J Infect Dis*. 2023. <https://doi.org/10.1016/j.ijid.2023.02.025>. S1201-9712(23)00076-0.
78. Nieves DJ, Heininger U. Bordetella pertussis. *Microbiol Spectr*. 2016;4(3). <https://doi.org/10.1128/microbiolspec.El10-0008-2015>.
79. Kuchar E, Karlikowska-Skwarnik M, Han S, Nitsch-Osuch A. Pertussis: history of the disease and current prevention failure. *Adv Exp Med Biol*. 2016;934:77–82.
80. Centers for Disease Control and Prevention. Diphtheria, Tetanus, and pertussis vaccines. <https://www.cdc.gov/vaccinesafety/vaccines/dtap-tdap-vaccine.html>, 2023. [accessed 17 April 2023].
81. Kapil P, Merkel TJ. Pertussis vaccines and protective immunity. *Curr Opin Immunol*. 2019;59:72–8.
82. Esposito S, Principi N. Immunization against pertussis in adolescents and adults. *Clin Microbiol Infect*. 2016;22(Suppl 5):S89-s95.
83. Aris E, Harrington L, Bhavsar A, Simeone JC, Ramond A, Papi A, et al. Burden of pertussis in COPD: a retrospective database study in England. *COPD*. 2021;18(2):157–69.
84. Centers for Disease Control and Prevention. Vaccines and preventable diseases. <https://www.cdc.gov/vaccines/vpd/pertussis/index.html>, 2022 [accessed 17 April 2023].
85. Warren-Gash C, Forbes H, Breuer J. Varicella and herpes zoster vaccine development: lessons learned. *Expert Rev Vaccines*. 2017;16(12):1191–201.
86. Harbecke R, Cohen JI, Oxman MN. Herpes zoster vaccines. *J Infect Dis*. 2021;224(12 Suppl 2):S429–42.
87. Centers for Disease Control and Prevention. Shingles vaccination. <https://www.cdc.gov/vaccines/vpd/shingles/public/shingrix/index.html>, 2022. [accessed 17 April 2023].
88. Centers for Disease Control and Prevention. Lung disease including asthma and adult vaccination. <https://www.cdc.gov/vaccines/adults/rec-vac/health-conditions/lung-disease.html>, 2021. [accessed 17 April 2023].
89. Truelove SA, Keegan LT, Moss WJ, Chaisson LH, Macher E, Azman AS, et al. Clinical and epidemiological aspects of

- diphtheria: a systematic review and pooled analysis. *Clin Infect Dis.* 2019;71(1):89–97.
90. Sharma NC, Efstratiou A, Mokrousov I, Mutreja A, Das B, Ramamurthy T. Diphtheria. *Nat Rev Dis Primers.* 2019;5(1):81. <https://doi.org/10.1038/s41572-019-0131-y>.
  91. Prygiel M, Mosiej E, Górska P, Zasada AA. Diphtheria-tetanus-pertussis vaccine: past, current & future. *Future Microbiol.* 2022;17:185–97.
  92. Finkelstein P, Teisch L, Allen CJ, Ruiz GJP. *medicine d.* Tetanus: a potential public health threat in times of disaster. *Prehosp Disaster Med.* 2017;32(3):339–42.
  93. Centers for Disease Control and Prevention. In: Hall E, Wodi A, Hamborsky J, Morelli V, Schillie S, eds. *Epidemiology and Prevention of Vaccine-Preventable Diseases*, 14th ed., Washington, D.C.: Public Health Foundation; 2021. editors.
  94. Rossetto O, Montecucco CJT. *Tables of toxicity of botulinum and tetanus neurotoxins.* Toxins (Basel). 2019;11(12):686. <https://doi.org/10.3390/toxins11120686>.
  95. Kyu HH, Mumford JE, Stanaway JD, Barber RM, Hancock JR, Vos T, et al. Mortality from tetanus between 1990 and 2015: findings from the global burden of disease study 2015. *BMC Public Health.* 2017;17(1):1. <https://doi.org/10.1186/s12889-016-3954-4>.
  96. Yadav DK, Yadav N, Khurana SMP. *Vaccines: present status and applications editors.* In: Verma AS, Singh A, eds. *Animal Biotechnology, Models in Discovery and Translation*, Cambridge, MA, USA: Academic Press; 2014:491–508.
  97. Callison C, Nguyen H. Tetanus prophylaxis. *StatPearls.* Treasure Island (FL): StatPearls Publishing; 2023.
  98. World Health Organization. Tetanus vaccines: WHO position paper, February 2017 - Recommendations. *Vaccine.* 2018;36(25):3573–5.
  99. Preuss CV, Kalava A, King KC. Prescription of controlled substances: benefits and risks. *StatPearls.* Treasure Island (FL): StatPearls Publishing; 2023.
  100. Rabadi T, Brady MF. Tetanus toxoid. *StatPearls.* Treasure Island (FL): StatPearls Publishing; 2023.
  101. World Health Organization. Protecting all against tetanus: guide to sustaining maternal and neonatal tetanus elimination (MNTE) and broadening tetanus protection for all populations. Geneva: World Health Organization; 2019.
  102. UK Health Security Agency. Complete routine immunization schedule. <https://www.gov.uk/government/publications/the-complete-routine-immunisation-schedule>, 2023 [accessed 11 May 2023].
  103. Ministero della Salute. Piano nazionale prevenzione vaccinale. <https://www.salute.gov.it/portale/vaccinazioni/dettaglioContenutiVaccinazioni.jsp?lingua=italiano&id=4828&area=vaccinazioni&menu=vuoto>, 2021. [accessed 11 May 2023].
  104. Centers for Disease Control and Prevention. Tetanus vaccination. <https://www.cdc.gov/vaccines/vpd/tetanus/index.html>, 2022. [accessed 11 May 2023].
  105. Direção-Geral de Saúde. Programa nacional de vacinação. <https://www.sns24.gov.pt/tema/vacinas/programa-nacional-de-vacinacao/#o-que-e-o-programa-nacional-de-vacinacao>, 2023. [accessed 11 May 2023].
  106. Berche P. History of measles. *Presse Med.* 2022;51(3):104149. <https://doi.org/10.1016/j.lpm.2022.104149>.
  107. de Vries RD, Mesman AW, Geijtenbeek TB, Duprex WP, de Swart RL. The pathogenesis of measles. *Curr Opin Virol.* 2012;2(3):248–55.
  108. Bester JC. Measles and measles vaccination: a review. *JAMA Pediatr.* 2016;170(12):1209–15.
  109. Buchanan R, Bonthius DJ. Measles virus and associated central nervous system sequelae. *Semin Pediatr Neurol.* 2012;19(3):107–14.
  110. Mina MJ, Metcalf CJ, de Swart RL, Osterhaus AD, Grenfell BT. Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality. *Science.* 2015;348(6235):694–9.
  111. Hirsch A. *Handbook of Geographical and Historical Pathology.* London: New Sydenham Society; 1883.
  112. Griffin DE. Measles vaccine. *Viral Immunol.* 2018;31(2):86–95.
  113. Enders JF, Peebles TC. Propagation in tissue cultures of cytopathogenic agents from patients with measles. *Proc Soc Exp Biol Med.* 1954;86(2):277–86.
  114. de Swart RL, Yüksel S, Osterhaus AD. Relative contributions of measles virus hemagglutinin-and fusion protein-specific serum antibodies to virus neutralization. *J Virol.* 2005;79(17):11547–51.
  115. Ota MO, Ndhlovu Z, Oh S, Piyasirisilp S, Berzofsky JA, Moss WJ, et al. Hemagglutinin protein is a primary target of the measles virus-specific HLA-A2-restricted CD8+ T cell response during measles and after vaccination. *J Infect Dis.* 2007;195(12):1799–807.
  116. Dixon MG, Ferrari M, Antoni S, Li X, Portnoy A, Lambert B, et al. Progress toward regional measles elimination—worldwide, 2000–2020. *MMWR Morb Mortal Wkly Rep.* 2021;70(45):1563.
  117. Centers for disease control and prevention vaccine (Shot) for measles. <https://www.cdc.gov/vaccines/parents/diseases/measles.html>, 2021. [accessed 17 April 2023].
  118. Luca S, Mihaescu T. History of BCG vaccine. *Maedica (Bucur).* 2013;8(1):53–8.
  119. Calmette A. *L'infection Bacillaire et la Tuberculose Chez L'homme et Chez Les animaux: Processus D'infection et de Défense, Étude Biologique et Expérimentale.* Paris: Masson et Cie; 1920.
  120. Ahmed A, Rakshit S, Adiga V, Dias M, Dwarkanath P, D'Souza G, et al. A century of BCG: impact on tuberculosis control and beyond. *Immunol Rev.* 2021;301(1):98–121.
  121. Lancione S, Alvarez JV, Alsdurf H, Pai M, Zwerling AA. Tracking changes in national BCG vaccination policies and practices using the BCG world Atlas. *BMJ Glob Health.* 2022;7(1):e007462. <https://doi.org/10.1136/bmjgh-2021-007462>.
  122. Minassian AM, Satti I, Poulton ID, Meyer J, Hill AV, McShane H. A human challenge model for mycobacterium tuberculosis using mycobacterium bovis bacille Calmette-Guerin. *J Infect Dis.* 2012;205(7):1035–42.
  123. Bisiaux A, Boussier J, Duffy D, Quintana-Murci L, Fontes M, Albert ML, et al. Deconvolution of the response to bacillus Calmette-Guérin reveals NF- $\kappa$ B-induced cytokines as autocrine mediators of innate immunity. *Front Immunol.* 2017;8:796. <https://doi.org/10.3389/fimmu.2017.00796>.
  124. Marakalala MJ, Martinez FO, Plüddemann A, Gordon S. Macrophage heterogeneity in the immunopathogenesis of tuberculosis. *Front Microbiol.* 2018;9:1028. <https://doi.org/10.3389/fmicb.2018.01028>.
  125. Feng CG, Britton WJ. CD4+ and CD8+ T cells mediate adoptive immunity to aerosol infection of Mycobacterium bovis bacillus Calmette-Guérin. *J Infect Dis.* 2000;181(5):1846–9.
  126. Ottenhoff TH, Verreck FA, Hoeve MA, van de Vosse E. Control of human host immunity to mycobacteria. *Tuberculosis (Edinb).* 2005;85(1–2):53–64.
  127. United Kingdom National Health Service. BCG (TB) vaccine side effects. <https://www.nhs.uk/conditions/vaccinations/bcg-tb-vaccine-side-effects/>, 2019. [accessed 17 April 2023].
  128. Moorlag SJCFM, Arts RJW, van Crevel R, Netea MG. Non-specific effects of BCG vaccine on viral infections. *Clin Microbiol Infect.* 2019;25(12):1473–8. <https://doi.org/10.1016/j.cmi.2019.04.020>.
  129. Arts RJ, Moorlag SJ, Novakovic B, Li Y, Wang S-Y, Oosting M, et al. BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity. *Cell Host Microbe.* 2018;23(1):89–100. e5. <https://doi.org/10.1016/j.chom.2017.12.010>.

130. Miller A., Reandelar M.J., Fasciglione K., Roumenova V., Li Y., Otazu G.H. Correlation between universal BCG vaccination policy and reduced mortality for COVID-19. medRxiv. 2020:2020.03.24.20042937.
131. Netea MG, van der Meer JW, van Crevel R. BCG vaccination in health care providers and the protection against COVID-19. J Clin Invest. 2021;131(2):e145545. <https://doi.org/10.1172/JCI145545>.
132. Amirlak L, Haddad R, Hardy JD, Khaled NS, Chung MH, Amirlak B. Effectiveness of booster BCG vaccination in preventing Covid-19 infection. Hum Vaccin Immunother. 2021;17(11):3913–5.
133. Li YP, Cai JW, Liao LJ, Ding H, Cao XJ, Zhu GD, Guo XG. Effect of BCG Vaccination against SARS-CoV-2 infection. Jpn J Infect Dis. 2022;75(3):302–8.
134. Wen J, Liu Q, Tang D, He JQ. Efficacy of BCG vaccination against COVID-19: systematic review and meta-analysis of randomized controlled trials. J Clin Med. 2023;12(3):1154. <https://doi.org/10.3390/jcm12031154>.
135. LI H, Wang Y. Clinical study of vaccinating BCG vaccine in bronchiolitis developed into child bronchial asthma in the future. Chin J Postgraduat Med. 2014;6:16–7. <https://doi.org/10.3760/cma.j.issn.1673-4904.2014.06.006>.